New combo therapy targets tough blood cancers in early trial
Disease control
Ongoing
This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC